Use of this treatment for localized prostate cancer has been decreasing since 2002, perhaps due to increasing use of radical prostatectomy.
Patients in the second lowest quintile of testosterone level had a 53% increased death risk compared with those in the highest quintile.
The combined treatment was associated with a reduced risk of biochemical and clinical progression compared with radiotherapy alone.
Penile traction therapy reduced curvature and significantly improved erectile function and hardness.
Danish study reveals a 10% prevalence of osteoporosis among men due to start androgen-deprivation therapy.
The nadir should be below 0.01 ng/mL because even levels of 0.01 to 0.2 ng/mL predict an increased risk of adverse outcomes.
New study also suggests that low preoperative hematocrit and albumin levels predict adverse outcomes.
Men who need a prostate biopsy should be offered TP as a possible alternative to TRUS-guided biopsy.
Men with high cholesterol and ED who used the drugs experienced a significant 3.2-point increase in IIEF score versus controls.
Cumulative rates of clinical success were 87.2% at 3 months, 80.2% at 18 months, and 72.3% at 36 months (long term).
It is associated with a decreased risk of disease progression compared with a wait-and-see approach.
Magnetic resonance imaging can identify men more likely to harbor intermediate- and high-risk tumors.
Higher circulating tumor cell counts are associated with an increased risk of death.
The treatment, however, is associated with a decreased risk of all-cause mortality in men at high risk of disease progression.
Trend follows the 2012 release of a U.S. Preventive Services Task Force recommendation against such testing.